Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women | Zendy

Loes Jaspers | Zendy; Frederik Feys | Zendy; Wichor M. Bramer | Zendy; Oscar H. Franco | Zendy; Peter Leusink | Zendy; Ellen Laan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women

Author(s) -

Loes Jaspers,

Frederik Feys,

Wichor M. Bramer,

Oscar H. Franco,

Peter Leusink,

Ellen Laan

Publication year - 2016

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2015.8565

Subject(s) - medicine , hypoactive sexual desire disorder , placebo , randomized controlled trial , adverse effect , meta analysis , psycinfo , sexual desire , blinding , clinical trial , medline , psychiatry , alternative medicine , human sexuality , gender studies , pathology , sociology , political science , law

In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, despite concern about suboptimal risk-benefit trade-offs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research